Literature DB >> 16769659

In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease.

R La Corte1, A Lo Mo Naco, A Locaputo, F Dolzani, F Trotta.   

Abstract

We studied the clinical features and autoantibody profile in 21 patients with antisynthetase syndrome (AS) comparing to 48 patients with classical polymyositis and dermatomyositis without AS. At presentation, the AS group showed more frequently the presence of interstitial lung disease (ILD), arthritis/arthralgia, mechanic's hand and anti-Ro/SSA antibodies. Patients without AS had more frequent proximal weakness and cutaneous erythematosus rash. Interestingly, the AS patients with associated anti-Ro/SS-A antibodies seem to be predisposed to the development of a more severe ILD, expressed as HRCT total score > or = 7. During a follow up of about 3 years (range 6-110 months), the presence of anti-Jo-1 antibody alone or in association with anti-Ro/SSA did not influence survival or a more severe prognosis of ILD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769659     DOI: 10.1080/08916930600623791

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  59 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients.

Authors:  Andrea Váncsa; I Csípo; J Németh; K Dévényi; L Gergely; K Dankó
Journal:  Rheumatol Int       Date:  2009-03-06       Impact factor: 2.631

3.  [Progressive respiratory failure and weakness in a 61-year-old woman].

Authors:  M Mahmud; U Schnoor; O M Steinmetz
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743

4.  Sonographic findings from inflammatory arthritis due to antisynthetase syndrome.

Authors:  John B Miller; Sonye K Danoff; Clifton O Bingham; Julie J Paik; Christopher A Mecoli; Eleni Tiniakou; Lisa Christopher-Stine; Jemima Albayda
Journal:  Clin Rheumatol       Date:  2019-02-27       Impact factor: 2.980

5.  Antisynthetase syndrome in pregnancy: A case and review of the literature.

Authors:  Lauren J Green; Lorraine O'Neill; Charlotte J Frise
Journal:  Obstet Med       Date:  2018-11-08

Review 6.  Squamous cell carcinoma of the lung associated with anti-Jo1 antisynthetase syndrome: a case report and review of the literature.

Authors:  G Boleto; J-M Perotin; J-P Eschard; J-H Salmon
Journal:  Rheumatol Int       Date:  2017-04-26       Impact factor: 2.631

Review 7.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 8.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

9.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631

10.  Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.

Authors:  Aryeh Fischer; Jeffrey J Swigris; Roland M du Bois; David A Lynch; Gregory P Downey; Gregory P Cosgrove; Stephen K Frankel; Evans R Fernandez-Perez; JoAnn Z Gillis; Kevin K Brown
Journal:  Respir Med       Date:  2009-06-03       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.